Comparison of 200 mg retarded release levodopa/carbidopa – with 150 mg levodopa/carbidopa/entacapone application: pharmacokinetics and efficacy in patients with Parkinson’s disease Article First Online: 14 June 2007 Received: 09 January 2007 Accepted: 22 May 2007 DOI:
Cite this article as: Müller, T., Ander, L., Kolf, K. et al. J Neural Transm (2007) 114: 1457. doi:10.1007/s00702-007-0773-x Summary.
The interval of line tracing performance is more associated to basal ganglia function due to the dependence on bradykinesia and rigidity. The other component of this task, the precision of execution of complex movement sequences, is more related to attention. We compared the motor response after once dosing of 200 mg retarded release LD (levodopa)/CD (carbidopa) and of 150 mg LD/CD/EN (entacapone) by rating of motor symptoms, by measurement of LD- and 3-O-methyldopa (3-OMD) plasma concentrations and by the outcomes of a line tracing task. Thirteen treated patients with Parkinson’s disease (PD) took one of the two tested LD formulations on two consecutive days under randomised, double blind, identical standardised conditions. No significant differences appeared regarding rated motor response and LD plasma concentrations, but 3-OMD only significantly went up after LD/CD intake. LD/CD/EN was superior to LD/CD regarding the attention related components of line tracing probably due to a hypothetically increased dopamine occurrence at the prefrontal cortex, which guides human behaviour.
Keywords: Levodopa; Parkinson’s disease; entacapone; retarded release References Arnsten, AF, Li, BM 2005 Neurobiology of executive functions: catecholamine influences on prefrontal cortical functions Biol Psychiatry 57 1377 1384 PubMed CrossRef Google Scholar Block, G, Liss, C, Reines, S, Irr, J, Nibbelink, D 1997 Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson’s disease. A multicenter 5-year study. The CR First Study Group Eur Neurol 37 23 27 PubMed Google Scholar Fabbrini, G, Juncos, JL, Mouradian, MM, Serrati, C, Chase, TN 1987 3-O-methyldopa and motor fluctuations in Parkinson’s disease Neurology 37 856 859 PubMed Google Scholar Fahn, S, Oakes, D, Shoulson, I, Kieburtz, K, Rudolph, A, Lang, A, Olanow, CW, Tanner, C, Marek, K 2004 Levodopa and the progression of Parkinson’s disease N Engl J Med 351 2498 2508 PubMed CrossRef Google Scholar Frank, MJ 2005 Dynamic dopamine modulation in the basal ganglia: a neurocomputational account of cognitive deficits in medicated and nonmedicated Parkinsonism J Cogn Neurosci 17 51 72 PubMed CrossRef Google Scholar Ghilardi, M, Ghez, C, Dhawan, V, Moeller, J, Mentis, M, Nakamura, T, Antonini, A, Eidelberg, D 2000 Patterns of regional brain activation associated with different forms of motor learning Brain Res 871 127 145 PubMed CrossRef Google Scholar Goetz, CG, LeWitt, PA, Weidenman, M 2003 Standardized training tools for the UPDRS activities of daily living scale: newly available teaching program Mov Disord 18 1455 1458 PubMed CrossRef Google Scholar Koller, WC, Hutton, JT, Tolosa, E, Capilldeo, R 1999 Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Carbidopa/Levodopa Study Group Neurology 53 1012 1019 PubMed Google Scholar Müller, T, Benz, S, Przuntek, H 2002 Tapping and peg insertion after levodopa intake in treated and de novo parkinsonian patients Can J Neurol Sci 29 73 77 PubMed Google Scholar Müller, T, Erdmann, C, Bremen, D, Schmidt, WE, Muhlack, S, Woitalla, D, Goetze, O 2006a Impact of gastric emptying on levodopa pharmacokinetics in Parkinson disease patients Clin Neuropharmacol 29 61 67 CrossRef Google Scholar Müller, T, Erdmann, C, Muhlack, S, Bremen, D, Przuntek, H, Goetze, O, Woitalla, D 2006b Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson’s disease J Neural Transm 113 1441 1448 CrossRef Google Scholar Müller, T, Kuhn, W, Schulte, T, Przuntek, H 2003 Intravenous amantadine sulphate application improves the performance of complex but not simple motor tasks in patients with Parkinson’s disease Neurosci Lett 339 25 28 PubMed CrossRef Google Scholar Müller, T, Schafer, S, Kuhn, W, Przuntek, H 2000 Correlation between tapping and inserting of pegs in Parkinson’s disease Can J Neurol Sci 27 311 315 PubMed Google Scholar Nakamura, T, Ghilardi, MF, Mentis, M, Dhawan, V, Fukuda, M, Hacking, A, Moeller, JR, Ghez, C, Eidelberg, D 2001 Functional networks in motor sequence learning: abnormal topographies in Parkinson’s disease Hum Brain Mapp 12 42 60 PubMed CrossRef Google Scholar Nieoullon, A, Coquerel, A 2003 Dopamine: a key regulator to adapt action, emotion, motivation and cognition Curr Opin Neurol 16 S3 S9 PubMed CrossRef Google Scholar Nutt, JG 2000 Effect of COMT inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients Neurology 55 S33 S37 PubMed Google Scholar Soares-da-Silva, P, Parada, A, Serrao, P 2000 The O-methylated derivative of L-DOPA, 3-O-methyl-L-DOPA, fails to inhibit neuronal and non-neuronal aromatic L-amino acid decarboxylase Brain Res 863 293 297 PubMed CrossRef Google Scholar Uekermann, J, Daum, I, Peters, S, Wiebel, B, Przuntek, H, Müller, T 2003 Depressed mood and executive dysfunction in early Parkinson’s disease Acta Neurol Scand 107 341 348 PubMed CrossRef Google Scholar